SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-186835
Filing Date
2020-07-02
Accepted
2020-07-02 16:09:15
Documents
7
Period of Report
2020-07-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d920444d8k.htm 8-K 25479
2 EX-1.1 d920444dex11.htm EX-1.1 180695
3 EX-4.1 d920444dex41.htm EX-4.1 60701
4 EX-5.1 d920444dex51.htm EX-5.1 16032
5 EX-99.1 d920444dex991.htm EX-99.1 9430
6 GRAPHIC g920444g0702135144486.jpg GRAPHIC 6456
7 GRAPHIC g920444g0702135343390.jpg GRAPHIC 6125
  Complete submission text file 0001193125-20-186835.txt   311357
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 201009356
SIC: 2834 Pharmaceutical Preparations